$6m · Seed · Wellness & Beauty · London, UK
DITTO, a London menstrual-health company developing supplements for cycle-related symptoms, has raised $6m in Seed funding. FoodLabs led the round, with returning investor Eka Ventures and angel investors participating. The company says the capital will expand its supplement portfolio, clinical research programme and consumer reach.
Research is part of the product
DITTO's first product, Premenstrual Daily, is a 10-ingredient daily supplement aimed at people experiencing PMS and related menstrual symptoms. The company uses beadlet technology to separate ingredients inside a capsule and control when they are released, an approach it says can limit ingredient interactions and improve consistency. Founder Alice van der Schoot combines nutrition science and neuroscience experience, while co-founder Adam Kugler previously worked in brand leadership.
The commercial model pairs a recurring 28-day supplement supply with research and educational content. That makes trust central to retention: customers need a reason to keep taking the product beyond an initial purchase, and product-level evidence can support that confidence more directly than broad category claims. DITTO's own site also offers subscription delivery, so the value of its research programme is commercial as well as scientific if stronger evidence helps sustain repeat use.
Capital for validation, not just distribution
DITTO reports a 40-person pilot study of its finished supplement across three menstrual cycles, with lower average symptom scores and 88% of participants reporting reduced symptom severity. The study is described as under peer review, so those company-reported findings should be treated as an early signal rather than settled clinical proof. The seed round gives DITTO room to extend that evidence base while developing additional targeted products.
That sequence matters in a supplements market where formulation claims are easy to make but product-specific evidence is harder and slower to build. FoodLabs said DITTO's research work, founders and delivery system drove its investment decision. If the company can turn further trials into credible evidence and clear consumer guidance, it may strengthen both product differentiation and the repeat-purchase economics of its direct-to-consumer model; if not, the business remains exposed to the same trust problem it is trying to solve.
Sources checked:
FoodLabs funding announcement · FoodLabs investment post · Nutraceutical Business Review · DITTO · Tech.eu Funding Explorer
Image: FoodLabs, via its official funding announcement.
